featured
Daratumumab, Lenalidomide, and Dexamethasone in Relapsed/Refractory Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Blood Cancer Journal
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Daratumumab, Lenalidomide, and Dexamethasone in Relapsed/Refractory Myeloma: A Cytogenetic Subgroup Analysis of POLLUX
Blood Cancer J 2020 Nov 03;10(11)111, JL Kaufman, MA Dimopoulos, D White, L Benboubker, G Cook, M Leiba, J Morton, P Joy Ho, K Kim, N Takezako, P Moreau, HJ Sutherland, H Magen, S Iida, JS Kim, H Miles Prince, T Cochrane, A Oriol, NJ Bahlis, A Chari, L O'Rourke, S Trivedi, T Casneuf, M Krevvata, J Ukropec, R Kobos, H Avet-Loiseau, SZ Usmani, J San-MiguelFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.